A novel chimeric antigen receptor T-cell therapy yielded an objective response rate of 82% in patients with refractory large B-cell lymphoma.

Conferences

Three studies presented at the ASH Annual Meeting and Exposition highlight the emerging role CAR T-cell therapies have in treating certain types of aggressive, refractory blood cancers.

News

A novel chimeric antigen receptor T-cell therapy yielded an objective response rate of 82% in patients with refractory large B-cell lymphoma.

Research in Review

Researchers report significantly improved response rates in patients with CLL treated with concurrent targeted therapy and CAR-T therapy.
Pembrolizumab improves response to chimeric antigen receptor T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia.
Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and CAR T-cell therapy tend to have high serum levels of a particular protein.
The authors review the foundational research in CAR-T therapy.
Subscribe to CAR-T Therapies